Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Kymera Therapeutics Inc (NQ: KYMR )

34.19 -0.47 (-1.36%)
Streaming Delayed Price Updated: 10:23 AM EDT, Apr 30, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Kymera Therapeutics Inc

< Previous 1 2 Next >
Kymera Therapeutics to Report First Quarter 2024 Financial Results on May 2
From Kymera Therapeutics, Inc.
Via GlobeNewswire
Kymera Therapeutics Announces Scientific Presentations at the American Association for Cancer Research 2024 Annual Meeting
From Kymera Therapeutics, Inc.
Via GlobeNewswire
Kymera Therapeutics Presents Preclinical Data for STAT6 and TYK2 First-In-Class, Oral Degrader Immunology Programs at the American Academy of Dermatology Annual Meeting
From Kymera Therapeutics, Inc.
Via GlobeNewswire
Kymera Therapeutics to Participate in Upcoming March Investor Conferences
From Kymera Therapeutics, Inc.
Via GlobeNewswire
Kymera Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides a Business Update
From Kymera Therapeutics, Inc.
Via GlobeNewswire
Kymera Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on February 22
From Kymera Therapeutics, Inc.
Via GlobeNewswire
Kymera Therapeutics to Present in Fireside Chat at the Guggenheim Healthcare Conference
From Kymera Therapeutics, Inc.
Via GlobeNewswire
Kymera Therapeutics Outlines Key 2024 Objectives and Strategy to Progress Leading Portfolio of Immunology and Oncology Programs
From Kymera Therapeutics, Inc.
Via GlobeNewswire
Kymera Therapeutics Announces Closing of Upsized $275 Million Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
From Kymera Therapeutics, Inc.
Via GlobeNewswire
Kymera Therapeutics Announces Pricing of $275 Million Public Offering
From Kymera Therapeutics, Inc.
Via GlobeNewswire
Kymera Therapeutics Announces Proposed Public Offering
From Kymera Therapeutics, Inc.
Via GlobeNewswire
R&D Day Highlights Kymera’s Immunology Strategy and Emerging Pipeline of Novel, First-in-Class Oral Degraders Addressing Multiple Highly Prevalent Immuno-inflammatory Diseases
From Kymera Therapeutics, Inc.
Via GlobeNewswire
Kymera Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference on Tuesday, January 9, 2024
From Kymera Therapeutics, Inc.
Via GlobeNewswire
Kymera Therapeutics to Host Virtual Immunology R&D Day on January 4
Company to provide update on its emerging pipeline of high-value immunology programs 
From Kymera Therapeutics, Inc.
Via GlobeNewswire
Kymera Therapeutics Presents Interim Results from STAT3 Degrader Phase 1 Clinical Trial at American Society of Hematology Annual Meeting
From Kymera Therapeutics, Inc.
Via GlobeNewswire
Kymera Therapeutics Announces First Patient Dosed in Phase 2 Atopic Dermatitis Clinical Trial of KT-474 (SAR444656), a First-in-Class, Investigational IRAK4 Degrader, Generating a $15 Million Payment from Sanofi
From Kymera Therapeutics, Inc.
Via GlobeNewswire
Kymera Therapeutics Announces Publication of Phase 1 Trial Results for KT-474 (SAR444656), a First-in-Class IRAK4 Degrader, in Nature Medicine
From Kymera Therapeutics, Inc.
Via GlobeNewswire
Kymera Therapeutics to Present New Clinical Data from the Phase 1 Trial of STAT3 Degrader KT-333 at the ASH Annual Meeting
From Kymera Therapeutics, Inc.
Via GlobeNewswire
Kymera Therapeutics Announces Third Quarter 2023 Financial Results and Provides a Business Update
From Kymera Therapeutics, Inc.
Via GlobeNewswire
Kymera Therapeutics to Participate in Upcoming November Investor Conferences
From Kymera Therapeutics, Inc.
Via GlobeNewswire
Kymera Therapeutics Announces First Patient Dosed in Phase 2 Hidradenitis Suppurativa Clinical Trial of KT-474 (SAR444656), a First-in-Class, Investigational IRAK4 Degrader, Generating $40 Million Payment from Sanofi
The dosing of the first patient in the Phase 2 Atopic Dermatitis (AD) clinical trial is expected later this quarter 
From Kymera Therapeutics, Inc.
Via GlobeNewswire
Kymera Therapeutics to Report Third Quarter 2023 Financial Results on November 2
From Kymera Therapeutics, Inc.
Via GlobeNewswire
Kymera Therapeutics Presents Preclinical Data Demonstrating Activity of MDM2 Degraders in Acute Myeloid Leukemia and Merkel Cell Carcinoma
From Kymera Therapeutics, Inc.
Via GlobeNewswire
Kymera Therapeutics Receives U.S. FDA Fast Track Designation for KT-333, a First-in-Class, Investigational STAT3 Degrader for the Treatment of Relapsed/Refractory Cutaneous T-Cell Lymphoma and Relapsed/Refractory Peripheral T-Cell Lymphoma
From Kymera Therapeutics, Inc.
Via GlobeNewswire
Kymera Therapeutics to Participate in Upcoming September Investor Conferences
From Kymera Therapeutics, Inc.
Via GlobeNewswire
Kymera Therapeutics Announces Second Quarter 2023 Financial Results and Provides a Business Update
From Kymera Therapeutics, Inc.
Via GlobeNewswire
Kymera Therapeutics to Report Second Quarter 2023 Financial Results on August 3
From Kymera Therapeutics, Inc.
Via GlobeNewswire
Kymera Therapeutics Receives FDA Orphan Drug Designation for KT-253, a Novel, Highly Potent and Selective MDM2 Degrader for the Treatment of Acute Myeloid Leukemia
From Kymera Therapeutics, Inc.
Via GlobeNewswire
Kymera Therapeutics’ STAT3 Degrader KT-333 and IRAKIMiD Degrader KT-413 Demonstrate Desired Target Knockdown and Safety with Continued Dose Escalation in Ongoing Phase I Clinical Trials
From Kymera Therapeutics, Inc.
Via GlobeNewswire
Kymera Therapeutics Announces Updated Clinical Data from the Phase 1 Trials of STAT3 Degrader KT-333 and IRAKIMiD Degrader KT-413
From Kymera Therapeutics, Inc.
Via GlobeNewswire
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.